The Global 3D Bioprinting Market in terms of revenue was estimated to be worth $1.3 billion in 2022 and is poised to reach $3.3 billion by 2027, growing at a CAGR of 20.8% from 2022 to 2027. The new version of the report includes the startup/SME company evaluation quadrant for 15 companies operating in the 3D bioprinting market. This updated section is the output of a comprehensive study of the key startup vendors offering 3D bioprinting products. From a list of more than 50 vendors, the top 15 were chosen. These vendors were evaluated based on market share, ranking, and product footprint, rated, and positioned on a 2×2 quadrant. Factors such as technological advancements in 3D bioprinters and biomaterials, increasing use of 3D bioprinting in the pharmaceutical and cosmetology industries, and rising public and private funding to support bioprinting research activities are driving market growth. However, a dearth of skilled professionals and high development and production costs are restraining the growth of this market.
Download PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=170201787
Browse in-depth TOC on “3D Bioprinting Market”
297 – Tables
38 – Figures
270 – Pages
Key players in the global 3D Bioprinting Market include BICO Group AB (US), Organovo Holdings Inc. (US), Allevi, Inc. (part of 3D Systems, Inc.) (US), CollPlant Biotechnologies Ltd. (Israel), regenHU (Switzerland), EnvisionTEC GmbH (part of Desktop Metal, Inc.) (Germany), Aspect Biosystems Ltd. (Canada), Advanced Solutions Life Sciences, LLC (US), and Regenovo Biotechnology Co., Ltd. (part of Shining 3D Tech Co., Ltd.) (China).
The 3D Bioprinters segment accounted for the largest share in the 3D Bioprinting market, by component, during the forecast period.
Based on component, the 3D bioprinting market is segmented into 3D bioprinters and bioinks. 3D bioprinters accounted for the larger market share in 2021. Technological advancements and the growing demand for organ transplants are the major factors driving the growth of this segment.
The Research applications subsegment accounted for the largest share of the application segment in the 3D Bioprinting market in 2021.
Based on application, the 3D bioprinting market is segmented into research applications and clinical applications. The research applications segment accounted for the larger share of the 3D bioprinting market in 2021. The market for research applications is further segmented into drug research, regenerative medicine, and 3D cell culture. Among these, the drug research segment accounted for the largest share of the market in 2021, due to the growing adoption of 3D bioprinting technology by biopharmaceutical companies.
The Research Organizations and Academic Institutes subsegment accounted for the largest share of the application segment in the 3D bioprinting market in 2021.
On the basis of end users, the 3D bioprinting market is segmented into research organizations and academic institutes, biopharmaceutical companies, and hospitals. Research organizations and academic institutes form the largest and fastest-growing end-user segment in this market. This can be attributed to the increasing collaborations between academic & research institutes and key market players for developing novel 3D-bioprinted products.
Request Sample Pages:https://www.marketsandmarkets.com/requestsampleNew.asp?id=170201787
North America is the largest region and Asia Pacific is the fastest-growing region of the 3D Bioprinting market in 2021.
Based on region, the 3D bioprinting market is segmented into North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa. In 2021, North America dominated the market, followed by Europe. The significant government and private investments to develop advanced 3D bioprinting technologies, the high adoption rate of these technologies, and the presence of key market players in the region are responsible for the large share of North America in the 3D bioprinting market. The Asia Pacific market is projected to grow at the highest CAGR during the forecast period.
Get 10% Free Customization on this Report: https://www.marketsandmarkets.com/requestCustomizationNew.asp?id=170201787
MarketsandMarkets™ provides quantified B2B research on 30,000 high growth niche opportunities/threats which will impact 70% to 80% of worldwide companies’ revenues. Currently servicing 7500 customers worldwide including 80% of global Fortune 1000 companies as clients. Almost 75,000 top officers across eight industries worldwide approach MarketsandMarkets™ for their painpoints around revenues decisions.
Our 850 fulltime analyst and SMEs at MarketsandMarkets™ are tracking global high growth markets following the “Growth Engagement Model – GEM”. The GEM aims at proactive collaboration with the clients to identify new opportunities, identify most important customers, write “Attack, avoid and defend” strategies, identify sources of incremental revenues for both the company and its competitors. MarketsandMarkets™ now coming up with 1,500 MicroQuadrants (Positioning top players across leaders, emerging companies, innovators, strategic players) annually in high growth emerging segments. MarketsandMarkets™ is determined to benefit more than 10,000 companies this year for their revenue planning and help them take their innovations/disruptions early to the market by providing them research ahead of the curve.
MarketsandMarkets’s flagship competitive intelligence and market research platform, “Knowledge Store” connects over 200,000 markets and entire value chains for deeper understanding of the unmet insights along with market sizing and forecasts of niche markets.
Mr. Aashish Mehra
630 Dundee Road
Northbrook, IL 60062
Research Insight: https://www.marketsandmarkets.com/ResearchInsight/cell-culture-market.asp
Visit Our Website: https://www.marketsandmarkets.com/
Content Source: https://www.marketsandmarkets.com/PressReleases/cell-culture.asp
Our Other Reports:
Veterinary Electrosurgical Market
Chromatography Reagents Market